Quantcast

Latest AbbVie Stories

2014-08-18 12:27:32

- Recipients will compete for public votes for a chance to win one of two Thriving Undergraduate and Graduate Scholar awards NORTH CHICAGO, Ill., Aug. 18, 2014 /PRNewswire/ -- AbbVie today announced the 40 outstanding students with cystic fibrosis (CF) who will each receive $2,500 to pursue their undergraduate or graduate school education during the 2014-2015 school year through the AbbVie CF Scholarship program. Voting for two of the 40 winners to earn the title of 2014 Thriving...

2014-08-04 08:27:33

- Results from Phase I program in glioblastoma multiforme presented at ASCO earlier this year NORTH CHICAGO, Ill., Aug. 4, 2014 /PRNewswire/ -- AbbVie (NYSE:ABBV) today announced the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA) have granted orphan drug designation to AbbVie's investigational compound ABT-414, an anti-epidermal growth factor receptor antibody drug conjugate, which is being evaluated for safety and efficacy in patients with...

2014-08-01 12:25:54

- AbbVie will donate $10 to Cystic Fibrosis Research, Inc. (CFRI) for every recipe collected between August 1 and September 15, 2014, up to $10,000 NORTH CHICAGO, Ill. and PALO ALTO, Calif., Aug. 1, 2014 /PRNewswire/ -- AbbVie (NYSE: ABBV) and Cystic Fibrosis Research, Inc. (CFRI) today announced a partnership to expand awareness of proper nutritional habits in the cystic fibrosis (CF) community through the CFChef Shares program. CFChef Shares will run from August 1 to September...

2014-07-22 12:30:17

Initiative to optimize patient care spearheaded by AbbVie and The Michael J. Fox Foundation to visit 11 cities in 2014 NEW YORK, July 22, 2014 /PRNewswire-USNewswire/ -- National Parkinson's organizations are working together to help provide Parkinson's patients and caregivers with knowledge and support to optimize their care through the "Partners in Parkinson's" strategic health initiative launched by The Michael J. Fox Foundation and AbbVie. Partners in Parkinson's offers...

2014-06-26 08:27:43

- Trial will measure investigational compound's efficacy and safety in patients with HER2-negative breast cancer, associated with BRCA 1, BRCA 2 mutations NORTH CHICAGO, Ill., June 26, 2014 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced the initiation of a Phase III clinical trial evaluating the safety and efficacy of its investigational compound, veliparib (ABT-888), when added to carboplatin and paclitaxel, two chemotherapeutic medicines, in patients with advanced breast...

2014-06-17 04:21:28

NORTH CHICAGO, Ill., June 17, 2014 /PRNewswire/ -- AbbVie (NYSE: ABBV) announced today that the Marketing Authorization Applications (MAAs) for its investigational, all-oral, interferon-free regimen for the treatment of adult patients with chronic genotype 1 (GT1) hepatitis C virus (HCV) infection have been validated and are under accelerated assessment by the European Medicines Agency (EMA). Accelerated assessment, which is designated to new medicines of major public health...

2014-06-13 16:23:26

NORTH CHICAGO, Ill., June 13, 2014 /PRNewswire/ -- AbbVie (NYSE: ABBV) announced today that the New Drug Application (NDA) for its investigational, all-oral, interferon-free regimen for the treatment of adult patients with chronic genotype 1 (GT1) hepatitis C virus (HCV) infection has been accepted by the U.S. Food and Drug Administration (FDA) and has been granted priority review. The NDA was submitted on April 21, 2014 and is supported by data from a large clinical program...

2014-06-11 04:21:56

- Findings Show Positive Association Between Adherence and Anti-TNF Therapy Compared to Conventional Therapy PARIS, June 11, 2014 /PRNewswire/ -- AbbVie (NYSE:ABBV) today announced results from its multi-country ALIGN study, which shows that across six chronic immune-mediated inflammatory diseases (IMIDs), adherence to treatment was generally higher in patients being treated with TNF inhibitors compared to patients treated with conventional therapy. Furthermore, patients who were...

2014-06-10 08:30:23

NORTH CHICAGO, Ill., June 10, 2014 /PRNewswire/ -- AbbVie (NYSE: ABBV) will participate in the Goldman Sachs 35(th) Annual Global Healthcare Conference on Wednesday, June 11, 2014. Bill Chase, executive vice president and chief financial officer, will take part in a question and answer session at 10:40 a.m. Central time. A live audio webcast of the question and answer session will be accessible through AbbVie's Investor Relations Web site at www.abbvieinvestor.com. An archived...

2014-06-03 08:32:34

NORTH CHICAGO, Ill., June 3, 2014 /PRNewswire/ -- AbbVie (NYSE: ABBV) will participate in the Jefferies 2014 Global Healthcare Conference on Wednesday, June 4, 2014. Scott Brun, M.D., vice president, pharmaceutical development, will take part in a question and answer session at 8:30 a.m. Central time. A live audio webcast of the question and answer session will be accessible through AbbVie's Investor Relations Web site at www.abbvieinvestor.com. An archived edition of the session...


Word of the Day
cenobite
  • One of a religious order living in a convent or in community; a monk: opposed to anchoret or hermit (one who lives in solitude).
  • A social bee.
This word comes from the Latin 'coenobium,' convent, which comes from the Greek 'koinobios,' living in community.
Related